RADEK SKODA to Cell Line, Tumor
This is a "connection" page, showing publications RADEK SKODA has written about Cell Line, Tumor.
Connection Strength
0.100
-
Identification of Hepatic-like EPO as a Cause of Polycythemia. N Engl J Med. 2025 May 01; 392(17):1684-1697.
Score: 0.036
-
Targeting compensatory MEK/ERK activation increases JAK inhibitor efficacy in myeloproliferative neoplasms. J Clin Invest. 2019 03 04; 129(4):1596-1611.
Score: 0.024
-
HSP27 is a partner of JAK2-STAT5 and a potential therapeutic target in myelofibrosis. Nat Commun. 2018 04 12; 9(1):1431.
Score: 0.022
-
ATP binding to the pseudokinase domain of JAK2 is critical for pathogenic activation. Proc Natl Acad Sci U S A. 2015 Apr 14; 112(15):4642-7.
Score: 0.018